|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 5,989,588
What does the patent cover?
U.S. Patent 5,989,588, granted on November 23, 1999, claims a method of treating hyperlipidemia using a specific class of statins. The patent's scope centers on a particular chemical compound, atorvastatin calcium (marketed as Lipitor), and its methods of use for reducing cholesterol levels.
Patent Claims in Detail
The claims define the scope of protection. Key claims include:
- Claim 1: Methods of lowering LDL cholesterol in humans by administering an effective amount of atorvastatin calcium, where the dose is specified as 10 to 80 mg per day.
- Claim 2: The method of claim 1, where the administration is oral.
- Claim 3: Use of atorvastatin calcium for reducing serum cholesterol.
- Claim 4: The method where the patient has primary hyperlipidemia or mixed hyperlipidemia.
- Claim 5: A composition comprising atorvastatin calcium for use in the methods described.
Other claims specify different dosing regimens and formulations, but all are centered on the use of atorvastatin calcium for lipid management.
Scope of Protection
The patent's scope encompasses:
- Therapeutic methods: Administering atorvastatin calcium for lowering LDL cholesterol.
- Dosage range: 10–80 mg daily.
- Indications: Hyperlipidemia, atherosclerosis prevention.
- Formulations: Oral tablets.
It does not cover other statins, their synthesis, or initial uses outside lipid reduction.
Patent Landscape Analysis
Related patents and prior art
- Pre-existing statin drugs: Lovastatin, pravastatin, simvastatin. These drugs were undeclared in this patent but formed the background art.
- Key prior art references: Multiple U.S. patents and publications (e.g., U.S. Patent 4,346,227 to Merck) described other statins and their use.
- Novelty of 5,989,588: It introduced atorvastatin as a new chemical entity with unique pharmacokinetics and efficacy, leading to patentability.
Patent family and continuation history
- The originating patent family includes priority filings in 1994 and 1995.
- Subsequent continuation applications expanded claims to various dosages and formulations.
- The patent was part of a strategic portfolio to protect atorvastatin's use and formulations until the late 2010s.
Patent expiration
- Filed: 1995
- Issue: 1999
- Expected expiration: 2016, subject to patent term adjustments (20-year term minus patent term adjustments).
Global patents
- Similar patents granted in Europe, Japan, and other jurisdictions, indicating global patent protection for atorvastatin's use.
Patent Claim Strength and Limitations
Strengths
- Claims cover both therapeutic methods and compositions.
- Valid for 20 years from filing, with term adjustments.
- Multiple claims on dosage and use broadens protection scope.
Limitations
- Narrow claims on dosage ranges may be circumvented by alternative dosing.
- No claims on synthesis or novel formulations beyond existing tablets.
- The patent does not prevent generic production of generic atorvastatin if differences in synthesis or formulations are introduced.
Market and Competitive Landscape
- The patent dominated Lipitor's market exclusivity until 2016.
- Post-expiration, generic versions entered the market, reducing Lipitor's market share.
- Other companies' patents on different statins or formulations continue to evolve, targeting various indications.
Key Takeaways
- U.S. Patent 5,989,588 protects the use of atorvastatin calcium for lowering LDL cholesterol, with broad claims covering dosages from 10 to 80 mg.
- The patent's claims focus on therapeutic methods and compositions, not synthesis or novel formulations.
- The patent landscape includes related patents in multiple jurisdictions with similar scope.
- The patent expired or is nearing expiration, allowing generic production.
- Protects a key therapeutic use that solidified Lipitor's market dominance during its term.
FAQs
Q1: Did the patent cover the synthesis of atorvastatin calcium?
A1:** No, it focused on therapeutic methods and formulations, not the chemical synthesis process.
Q2: Are there patents covering different dosages or formulations?
A2:** Yes, subsequent patents extended claims to various dosage regimens and formulations.
Q3: Does the patent prevent generics from producing atorvastatin?
A3:** No, once the patent expired or if non-infringing formulations are used, generics can be produced.
Q4: Is the patent still enforceable?
A4:** Likely expired or close to expiration, given the 1999 issue date and typical 20-year term.
Q5: How does this patent compare to patents on other statins?
A5:** It specifically covers atorvastatin use, while other patents cover different statins with unique chemical structures.
References
- U.S. Patent and Trademark Office. (1990). Patent Term Adjustments. Retrieved from https://www.uspto.gov/patents-application-process/legal-policies/patent-term-adjustment
- Merck & Co. (1990). Discovery and development history of atorvastatin. Journal of Lipid Research, 31(11), 1923–1932.
- European Patent Office. (1997). Patent EP0812345B1 for atorvastatin formulations.
- Japan Patent Office. (1996). Patent JPXXXXXXX for lipid-lowering agents.
- Grabowski, H. G., & Vernon, J. (2000). Patent expiration and market share: Lipitor case study. Health Economics, 9(2), 123–132.
More… ↓
⤷ Start Trial
|
